- - Last updated Apr 09, 2026 14:08 UTC

URGN

Auto-created research stub. Run deep research to populate.

Judgment

WAIT

Conviction: LOW
Reassess: -

Auto-created placeholder.

Company Snapshot

Auto-created research stub. Run deep research to populate.

Price Targets

Entry

Trim

Stop Loss

Investment Thesis

Auto-created research stub. Awaiting analysis.

What Changes The Call

Upgrade Triggers

No upgrade triggers listed.

Downgrade Triggers

No downgrade triggers listed.

Scenarios

Scenario	Probability	Price Target	Timeframe	Main Driver	Outcome
No scenarios available.

Market Sentiment

Positioning: -

Not yet analyzed.

Sources cited: []

Insider Activity

Pattern: -

Not yet analyzed.

Net direction: -

10-K Analysis

Latest filing: - (10-K) · -

Status: Queued

Signal: -

Analyzed: - · Score: -/10

Analysis queued.

Chatter (X Search)

No recent chatter captured.

Source Mentions

DannyTrades

No recent DannyTrades mentions.

Substack

No recent Substack mentions.

High-Credibility Twitter

Apr 10, 2026 23:56 UTC · Twitter · Tier 1
@Zeecontrarian1 link — research
Apr 10, 2026 23:53 UTC · Twitter · Tier 1
@Zeecontrarian1 link — Jefferies initiates $URGN with a $40 price target, implying 100% upside
Apr 09, 2026 22:48 UTC · Twitter · Tier 1
@Zeecontrarian1 link — Zusduri underpins the URGN story, w/ strong ph.III efficacy/durability positioning a non-surgical alternative to repeat TURBT in recurrent non-muscle invasive bladder cancer (IR-NMIBC)
Apr 09, 2026 13:59 UTC · Twitter · Tier 1
@Zeecontrarian1 link — research

Source Attribution

Event count: -

No sources listed.

n/a

Research History

Apr 09, 2026

Auto-created research stub